What Does an Oncologist Do

An oncologist is a physician who specializes in the diagnosis, staging, and treatment of cancer across its full biological and clinical complexity. This page covers the core scope of oncology practice, the structured process through which oncologists evaluate and manage malignant disease, the clinical scenarios that bring patients into oncology care, and the boundaries that define when oncology expertise is required versus when other specialists take primary responsibility. Understanding what oncologists actually do clarifies how cancer care is organized and why referral pathways matter.

Definition and Scope

An oncologist's practice encompasses far more than prescribing chemotherapy. The American Board of Internal Medicine (ABIM), which oversees Medical Oncology Board Certification, defines the discipline as requiring competency in cancer biology, pharmacology, clinical trial methodology, palliative medicine, and end-of-life care alongside direct disease management. The American Board of Radiology (ABR) and the American Board of Surgery (ABS) govern parallel certifications for radiation and surgical oncologists respectively, each with distinct scopes.

Three primary types of oncologist operate within distinct procedural boundaries:

1. Medical oncologists — manage systemic therapies including chemotherapy, immunotherapy, targeted therapy, and hormone therapy; they typically serve as the primary coordinator of a patient's cancer care team.
2. Radiation oncologists — design and supervise radiation treatment plans, working with dosimetrists and physicists to deliver ionizing radiation with millimeter-level precision to tumor volumes.
3. Surgical oncologists — perform tumor resections, sentinel lymph node biopsies, and cytoreductive procedures; their scope is defined by anatomical site and the technical demands of oncologic surgery.

A fourth major category, hematologic oncology, addresses blood-based malignancies such as leukemia and lymphoma, often requiring bone marrow evaluation and stem cell transplantation protocols distinct from solid tumor management.

The full types of oncologists and their subspecialties reflect a field where no single physician type manages all disease presentations.

How It Works

Oncology care follows a structured sequence from initial suspicion through active treatment and long-term surveillance. The process is not linear in practice but contains discrete, identifiable phases.

1. Diagnostic workup — The oncologist reviews imaging, pathology reports, and laboratory data. Tissue diagnosis via biopsy is mandatory before any treatment decision; the American Society of Clinical Oncology (ASCO) emphasizes that no systemic therapy should begin without histologic or cytologic confirmation of malignancy.
2. Staging and grading — Tumors are classified using the American Joint Committee on Cancer (AJCC) TNM system, which scores tumor size (T), lymph node involvement (N), and metastatic status (M) on standardized scales. Stage I through Stage IV designations carry direct prognostic and therapeutic implications; the AJCC publishes the Cancer Staging Manual (currently in its 8th edition) as the governing reference.
3. Multidisciplinary tumor board review — For most solid tumors and hematologic malignancies, a multidisciplinary team (MDT) of oncologists, radiologists, pathologists, and surgeons reviews the case collectively before finalizing a treatment plan. The National Comprehensive Cancer Network (NCCN) guidelines, updated annually across more than 50 cancer types, provide the evidence-based framework against which individual treatment decisions are benchmarked.
4. Treatment delivery and monitoring — The oncologist prescribes, monitors, and adjusts systemic therapies; interprets response assessments via imaging and tumor markers; and manages treatment-related toxicities. Molecular profiling and biomarker testing increasingly drives therapy selection, particularly in lung, breast, and colorectal cancers where targeted mutations dictate drug choice.
5. Survivorship and surveillance — After active treatment, oncologists oversee structured follow-up schedules defined by disease type and treatment history, monitoring for recurrence and managing late effects of therapy. The regulatory context for oncology shapes how these follow-up protocols are documented and reimbursed under CMS (Centers for Medicare & Medicaid Services) standards.

Common Scenarios

Oncologists encounter patients at markedly different points in the disease trajectory:

• New cancer diagnosis following abnormal screening — A patient with an abnormal screening result from a mammogram, colonoscopy, or low-dose CT lung scan is referred for oncologic evaluation. The oncologist confirms staging and initiates the treatment sequence.
• Suspected malignancy from symptom presentation — Unexplained weight loss, fatigue, or persistent pain may prompt primary care referral before a confirmed diagnosis exists. The oncologist directs the diagnostic workup to rule in or out malignancy.
• High-risk genetic profile — Patients carrying BRCA1/BRCA2 mutations or Lynch syndrome variants, identified through genetic testing and counseling, may enter an oncologist's practice for risk-reduction management before any cancer is present.
• Recurrence or progression — Patients who complete initial treatment and later show evidence of disease recurrence return to oncology care, often requiring reassessment of molecular profile and enrollment in clinical trials investigating second-line or novel therapies.
• Palliative intent — When curative treatment is not achievable, oncologists manage disease-directed therapy alongside palliative care teams to control symptoms and preserve quality of life. This represents a distinct treatment goal, not an absence of active care.

Decision Boundaries

Oncologists operate within defined jurisdictional and clinical boundaries. Pathologists, not oncologists, render the definitive tissue diagnosis. Interventional radiologists perform image-guided biopsies in many institutions. Geneticists and genetic counselors interpret germline risk, though oncologists interpret somatic mutation data for treatment selection.

The threshold for oncology referral is not identical across cancer types. The NCCN and ASCO publish disease-specific referral criteria; primary care physicians are expected to refer upon confirmed or highly suspicious malignancy, not merely elevated tumor markers in isolation, since markers such as PSA and CA-125 carry significant false-positive rates documented in the U.S. Preventive Services Task Force (USPSTF) screening evidence reviews.

Oncologists also operate within the broader scope of oncology as a discipline and within the framework of cancer biology outlined across the oncology resource index, which situates individual specialties within the full continuum from prevention through survivorship.

References

• American Board of Internal Medicine (ABIM) — Medical Oncology Certification
• American Joint Committee on Cancer (AJCC) — Cancer Staging Manual, 8th Edition
• National Comprehensive Cancer Network (NCCN) — Clinical Practice Guidelines in Oncology
• American Society of Clinical Oncology (ASCO) — Clinical Practice Guidelines
• U.S. Preventive Services Task Force (USPSTF) — Cancer Screening Recommendations
• Centers for Medicare & Medicaid Services (CMS) — Oncology Care Model
• American Board of Radiology (ABR) — Radiation Oncology Certification

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)